Dimitrijevic Marija, Calamac Marina, Djurmez Ognjen, Stanic Nemanja, Gavrilovic Dusica, Bozovic-Spasojevic Ivana
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, Serbia.
Ther Adv Med Oncol. 2025 Jul 30;17:17588359251356105. doi: 10.1177/17588359251356105. eCollection 2025.
Ovarian function suppression (OFS) and premature menopause lead to side effects that significantly worsen the quality of life for young women with hormone receptor-positive early breast cancer (HR+ eBC).
We retrospectively analyzed the most common side effects of OFS and endocrine therapy (ET) in young women with HR+ eBC.
This analysis was designed as a combined cohort study according to STROBE criteria.
We retrospectively identified 118 patients (pts); after excluding pts with luteinizing hormone-releasing hormone analogs given for fertility preservation only and pts with permanent castration (surgical or by irradiation), 100 pts were included in the final analysis. We analyzed side effects that were represented by more than 10% of patients at any predefined time points. We looked at the frequency and dynamics of these side effects over time-baseline, 6th, 12th, 18th, 24th, 30th, and 36th month according to three categories-the entire population, according to age (younger and older than 40 years), and according to previous treatment (chemotherapy or not).
The most commonly reported side effects among the entire patient group were vasomotor symptoms, particularly hot flashes and night sweats. Sleep disturbances and anxiety were also reported, though less frequently. The most significant worsening of vasomotor symptoms occurred within the first 6 months. Women under 40 years of age reported night sweats and sleep disturbances more often than women aged 40 and older at all time points, with statistically significant differences observed at 30 months for both symptoms and at 12 months for night sweats alone. Among patients who did not receive CT, hot flashes were frequently reported; however, only night sweats showed a statistically significant difference at 6 months compared to the group that did receive CT. No significant differences were found in the frequency of sleep disturbances or anxiety between these groups.
Young women with HR+ eBC undergoing OFS plus ET commonly report side effects in clinical practice. The most frequently reported symptoms are hot flashes, night sweats, sleep disturbances, and anxiety. All symptoms were more pronounced at the 30-month follow-up compared to baseline.
卵巢功能抑制（OFS）和过早绝经会导致副作用，显著恶化激素受体阳性早期乳腺癌（HR+ eBC）年轻女性的生活质量。
我们回顾性分析了HR+ eBC年轻女性中OFS和内分泌治疗（ET）最常见的副作用。
根据STROBE标准，本分析设计为一项联合队列研究。
我们回顾性确定了118例患者（pts）；在排除仅为保留生育功能而给予促性腺激素释放激素类似物的患者以及永久性去势（手术或放疗）的患者后，100例患者纳入最终分析。我们分析了在任何预定义时间点有超过10%患者出现的副作用。我们根据三个类别——总体人群、年龄（40岁以下和40岁以上）以及既往治疗情况（是否接受化疗），观察了这些副作用随时间（基线、第6、12、18、24、30和36个月）的频率和变化情况。
在整个患者组中，最常报告的副作用是血管舒缩症状，尤其是潮热和盗汗。也报告了睡眠障碍和焦虑，但频率较低。血管舒缩症状最显著的恶化发生在最初6个月内。40岁以下的女性在所有时间点报告盗汗和睡眠障碍的频率均高于40岁及以上的女性，在30个月时两种症状以及仅在12个月时盗汗均观察到统计学显著差异。在未接受CT的患者中，潮热报告频繁；然而，与接受CT的组相比，仅在6个月时盗汗显示出统计学显著差异。这些组之间在睡眠障碍或焦虑的频率上未发现显著差异。
接受OFS加ET的HR+ eBC年轻女性在临床实践中普遍报告有副作用。最常报告的症状是潮热、盗汗、睡眠障碍和焦虑。与基线相比，所有症状在30个月随访时更为明显。
